Acrux Valuation
Is ACR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ACR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ACR (A$0.05) is trading below our estimate of fair value (A$0.74)
Significantly Below Fair Value: ACR is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACR?
Key metric: As ACR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ACR's PS Ratio? | |
|---|---|
| PS Ratio | 2.6x |
| Sales | AU$5.09m |
| Market Cap | AU$13.37m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | -1.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ACR's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.8x | ||
FRE Firebrick Pharma | 4x | n/a | AU$10.9m |
ECS ECS Botanics Holdings | 1.1x | n/a | AU$21.9m |
IXC Invex Therapeutics | 4.7x | n/a | AU$5.7m |
RNO Rhinomed | 1.4x | n/a | AU$11.5m |
ACR Acrux | 2.6x | 34.0% | AU$13.4m |
Price-To-Sales vs Peers: ACR is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (2.8x).
Price to Sales Ratio vs Industry
How does ACR's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?
Price-To-Sales vs Industry: ACR is good value based on its Price-To-Sales Ratio (2.6x) compared to the Australian Pharmaceuticals industry average (4.7x).
Price to Sales Ratio vs Fair Ratio
What is ACR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.6x |
| Fair PS Ratio | 2.1x |
Price-To-Sales vs Fair Ratio: ACR is expensive based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Little Green Pharma
AU$39.2m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
0%
1Y
6.1%
AVITA Medical
US$339.9m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.92
7D
2.3%
1Y
25.0%
AVITA Medical
US$342.3m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.97
7D
0.3%
1Y
19.6%